Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Cervical Cancer | Research

Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2)

Authors: Setareh Akhavan, Abbas Alibakhshi, Mahdieh Parsapoor, Abbas Alipour, Elahe Rezayof

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Cervical cancer is one of the most common malignancies among women. Appropriate and timely treatment of these patients can reduce the complications and increase their survival. The objective of this study was to compare neoadjuvant chemotherapy plus radical hysterectomy (NACTRH) and chemo-radiotherapy (CRT) in patients with bulky cervical cancer (stage IB3 & IIA2).

Material and methods

The medical records of patients with bulky cervical cancer (stage IB3 & IIA2) that received NACTRH or CRT between 2007 and 2017 were evaluated for therapeutic effects. Demographic characteristics, complications of chemo-radiotherapy and neoadjuvant chemotherapy, were collected in a researcher-made questionnaire. Our primary outcome was comparison of overall survival (OS), and disease-free survival (DFS) between two groups receiving NACTRH and CRT modalities.

Results

One-hundred and twenty three patients were enrolled in the study. The median age and the proportion of patients with stage IIA2 were higher in the CRT group compared to the NACTRH group (p < 0.05). The medians (95% CI) OS were 3.64 (3.95–6.45) and 3.9 (3.53–4.27) years in the NACTRH and CRT groups, respectively (P = 0.003). There were 16 (34.8%) and 22 (43.1%) recurrences in the NACTRH and CRT group, respectively (P = 0.4). The median (95% CI) DFS was 4.5 (3.88–5.12) years in the NACTRH group and 3.6 (2.85–4.35) years in the CRT group (P = 0.004). The 3-year OS rate in NACTRH and CRT groups were 97 and 90% respectively. The 3-year DFS rate in NACTRH and CRT groups were 88 and 66% respectively.

Conclusions

NACTRH is associated with a higher OS and DFS compared to CRT.

Marchetti C, De Felice F, Di Pinto A, Romito A, Musella A, et al. Survival Nomograms after curative Neoadjuvant chemotherapy and radical surgery for stage IB2-IIIB cervical Cancer. Cancer Res Treat. 2018;50(3):768–76. https://doi.org/10.4143/crt.2017.141.CrossRefPubMed

Musa J, Achenbach CJ, O'Dwyer LC, Evans CT, McHugh M, Hou L, et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: a systematic review and meta-analysis. PLoS One. 2017;12(9):e0183924. https://doi.org/10.1371/journal.pone.0183924.CrossRefPubMedPubMedCentral

Hansen EK, Roach M. Handbook of evidence-based radiation oncology: Springer; 2018. p. 631–52.CrossRef

Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23(30):7428–36. https://doi.org/10.1200/JCO.2004.00.3996.CrossRefPubMed

Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 2008;110(3):308–15. https://doi.org/10.1016/j.ygyno.2008.05.026.CrossRefPubMed

Hu T, Li S, Chen Y, Shen J, Li X, Huang K, et al. Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria. Eur J Cancer. 2012;48(15):2353–60. https://doi.org/10.1016/j.ejca.2012.03.015.CrossRefPubMed

Kumar L, Gupta S. Integrating chemotherapy in the Management of Cervical Cancer: a critical appraisal. Oncology. 2016;91(Suppl 1):8–17. https://doi.org/10.1159/000447576.CrossRefPubMed

Robova H, Rob L, Halaska MJ, Pluta M, Skapa P, Strnad P, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecol Oncol. 2013;128(1):49–53. https://doi.org/10.1016/j.ygyno.2012.10.002.CrossRefPubMed

Zhao H, He Y, Yang SL, Zhao Q, Wu YM. Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis. Onco Targets Ther. 2019;12:1881–91. https://doi.org/10.2147/OTT.S186451.CrossRefPubMedPubMedCentral

10.

Wang PH, Chang YH, Yang YH, Chang WH, Huang SY, Lai CR, et al. Outcome of patients with bulky IB (≥ 6 cm) cervical squamous cell carcinoma with and without cisplatin-based neoadjuvant chemotherapy. Taiwan J Obstet Gynecol. 2014;53(3):330–6. https://doi.org/10.1016/j.tjog.2014.05.001.CrossRefPubMed

11.

Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017;28(3):e34. https://doi.org/10.3802/jgo.2017.28.e34.CrossRefPubMedPubMedCentral

12.

Gong L, Lou JY, Wang P, Zhang JW, Liu H, Peng ZL. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer. Int J Gynaecol Obstet. 2012;117(1):23–6. https://doi.org/10.1016/j.ijgo.2011.11.017.CrossRefPubMed

13.

Hsieh HY, Huang JW, Lu CH, Lin JC, Wang L. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/− neoadjuvant chemotherapy. J Formos Med Assoc. 2019;118(1 Pt 1):99–108. https://doi.org/10.1016/j.jfma.2018.01.015.CrossRefPubMed

14.

Qin T, Zhen J, Zhou M, Wu H, Ren R, Qu B, et al. Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: a retrospective cohort study. Int J Surg. 2016;30:121–5. https://doi.org/10.1016/j.ijsu.2016.04.038.CrossRefPubMed

15.

Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, et al. Neoadjuvant chemotherapy with Taxane and platinum followed by radical hysterectomy for stage IB2-IIB cervical Cancer: impact of histology type on survival. J Clin Med. 2019;8(2):156. https://doi.org/10.3390/jcm8020156.CrossRefPubMedCentral

16.

Ujihira T, Ota T, Kusunoki S, Sugimori Y, Kimura M, Kaneda H, et al. Outcome of Neoadjuvant intra-arterial chemotherapy and radical hysterectomy for treatment of bulky stage IB to stage IIB uterine cervical Cancer: can postoperative irradiation be avoided? Int J Gynecol Cancer. 2016;26(7):1258–63. https://doi.org/10.1097/IGC.0000000000000753.CrossRefPubMed

17.

Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171–81. https://doi.org/10.1586/14737140.2015.1079777.CrossRefPubMed

18.

Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–24. https://doi.org/10.1016/j.ejso.2012.09.003.CrossRefPubMed

19.

Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;83:101945. https://doi.org/10.1016/j.ctrv.2019.101945.CrossRefPubMed

20.

Shrivastava SK, Mahantshetty U, Narayan K. Principles of radiation therapy in low-resource and well-developed settings, with particular reference to cervical cancer. Int J Gynaecol Obstet. 2015;131(Suppl 2):S153–8. https://doi.org/10.1016/j.ijgo.2015.06.013 PMID: 26433673.CrossRefPubMed

21.

Haque W, Verma V, Fakhreddine M, Hatch S, Butler EB, Teh BS. Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: analysis of the National Cancer Data Base. Gynecol Oncol. 2017;144(1):28–33. https://doi.org/10.1016/j.ygyno.2016.10.033.CrossRefPubMed

22.

Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol. 2009;20(1):22–7. https://doi.org/10.3802/jgo.2009.20.1.22.CrossRefPubMedPubMedCentral

23.

Wan T, Huang H, Liu JH, Li Z, Feng YL. Response to neoadjuvant chemotherapy on locally advanced cervical cancer and long-term follow-up outcome. Zhonghua Yi Xue Za Zhi. 2010;90(43):3045–8 Chinese.PubMed

24.

Sardi JE, Boixadera MA, Sardi JJ. Neoadjuvant chemotherapy in cervical cancer: a new trend. Curr Opin Obstet Gynecol. 2005;17(1):43–7. https://doi.org/10.1097/00001703-200502000-00008.CrossRefPubMed

25.

Ferrandina G, Gallotta V, Federico A, Fanfani F, Ercoli A, Chiantera V, et al. Minimally invasive approaches in locally advanced cervical Cancer patients undergoing radical surgery after Chemoradiotherapy: a propensity score analysis. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-09302-y.

Title: Comparison of therapeutic effects of chemo-radiotherapy with neoadjuvant chemotherapy before radical surgery in patients with bulky cervical carcinoma (stage IB3 & IIA2)
Authors: Setareh Akhavan
Abbas Alibakhshi
Mahdieh Parsapoor
Abbas Alipour
Elahe Rezayof
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Cervical Cancer
Cervical Cancer
Radiotherapy
Cytostatic Therapy
Hysterectomy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08416-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Material and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning

Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center

The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma

A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer

Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma

Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer